These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32031965)

  • 1. FOXO1 as a tumor suppressor inactivated via AR/ERβ signals in urothelial cells.
    Ide H; Mizushima T; Jiang G; Goto T; Nagata Y; Teramoto Y; Inoue S; Li Y; Kashiwagi E; Baras AS; Netto GJ; Kawahara T; Miyamoto H
    Endocr Relat Cancer; 2020 Apr; 27(4):231-244. PubMed ID: 32031965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear Factor-κB Promotes Urothelial Tumorigenesis and Cancer Progression via Cooperation with Androgen Receptor Signaling.
    Inoue S; Ide H; Mizushima T; Jiang G; Netto GJ; Gotoh M; Miyamoto H
    Mol Cancer Ther; 2018 Jun; 17(6):1303-1314. PubMed ID: 29592878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression.
    Kawahara T; Shareef HK; Aljarah AK; Ide H; Li Y; Kashiwagi E; Netto GJ; Zheng Y; Miyamoto H
    Oncotarget; 2015 Oct; 6(30):29860-76. PubMed ID: 26342199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GATA3 in the urinary bladder: suppression of neoplastic transformation and down-regulation by androgens.
    Li Y; Ishiguro H; Kawahara T; Miyamoto Y; Izumi K; Miyamoto H
    Am J Cancer Res; 2014; 4(5):461-73. PubMed ID: 25232488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
    Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
    Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATF2 promotes urothelial cancer outgrowth via cooperation with androgen receptor signaling.
    Inoue S; Mizushima T; Ide H; Jiang G; Goto T; Nagata Y; Netto GJ; Miyamoto H
    Endocr Connect; 2018 Dec; 7(12):1397-1408. PubMed ID: 30521479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder.
    Miyamoto H; Yao JL; Chaux A; Zheng Y; Hsu I; Izumi K; Chang C; Messing EM; Netto GJ; Yeh S
    BJU Int; 2012 Jun; 109(11):1716-26. PubMed ID: 22221549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathological and prognostic significance of the expression of sex hormone receptors in bladder cancer: A meta-analysis of immunohistochemical studies.
    Ide H; Inoue S; Miyamoto H
    PLoS One; 2017; 12(3):e0174746. PubMed ID: 28362839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the androgen receptor in urothelial cancer.
    Inoue S; Mizushima T; Miyamoto H
    Mol Cell Endocrinol; 2018 Apr; 465():73-81. PubMed ID: 28652170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor.
    Fan W; Yanase T; Morinaga H; Okabe T; Nomura M; Daitoku H; Fukamizu A; Kato S; Takayanagi R; Nawata H
    J Biol Chem; 2007 Mar; 282(10):7329-38. PubMed ID: 17202144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumor recurrence.
    Izumi K; Ito Y; Miyamoto H; Miyoshi Y; Ota J; Moriyama M; Murai T; Hayashi H; Inayama Y; Ohashi K; Yao M; Uemura H
    Oncotarget; 2016 Mar; 7(12):14153-60. PubMed ID: 26885620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GABBR2 as a Downstream Effector of the Androgen Receptor Induces Cisplatin Resistance in Bladder Cancer.
    Elahi Najafi MA; Yasui M; Teramoto Y; Tatenuma T; Jiang G; Miyamoto H
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ELK1 promotes urothelial tumorigenesis in the presence of an activated androgen receptor.
    Inoue S; Ide H; Mizushima T; Jiang G; Kawahara T; Miyamoto H
    Am J Cancer Res; 2018; 8(11):2325-2336. PubMed ID: 30555747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.
    Kawahara T; Ide H; Kashiwagi E; El-Shishtawy KA; Li Y; Reis LO; Zheng Y; Miyamoto H
    Urol Oncol; 2016 Oct; 34(10):432.e15-23. PubMed ID: 27330033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells.
    Liu P; Li S; Gan L; Kao TP; Huang H
    Cancer Res; 2008 Dec; 68(24):10290-9. PubMed ID: 19074897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.
    Anestis A; Sarantis P; Theocharis S; Zoi I; Tryfonopoulos D; Korogiannos A; Koumarianou A; Xingi E; Thomaidou D; Kontos M; Papavassiliou AG; Karamouzis MV
    J Cancer Res Clin Oncol; 2019 May; 145(5):1221-1233. PubMed ID: 30805773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells.
    Zheng Y; Izumi K; Yao JL; Miyamoto H
    Endocr Relat Cancer; 2011 Aug; 18(4):451-64. PubMed ID: 21613411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor-β expression and pharmacological targeting in bladder cancer.
    Kauffman EC; Robinson BD; Downes M; Marcinkiewicz K; Vourganti S; Scherr DS; Gudas LJ; Mongan NP
    Oncol Rep; 2013 Jul; 30(1):131-8. PubMed ID: 23612777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of α
    Nagata Y; Kawahara T; Goto T; Inoue S; Teramoto Y; Jiang G; Fujimoto N; Miyamoto H
    Am J Cancer Res; 2020; 10(12):4386-4398. PubMed ID: 33415006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzalutamide as an androgen receptor inhibitor prevents urothelial tumorigenesis.
    Kawahara T; Inoue S; Kashiwagi E; Chen J; Ide H; Mizushima T; Li Y; Zheng Y; Miyamoto H
    Am J Cancer Res; 2017; 7(10):2041-2050. PubMed ID: 29119053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.